Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health (3-7471)
This publication has 24 references indexed in Scilit:
- Preeclampsia: The Role of Angiogenic Factors in Its PathogenesisPhysiology, 2009
- Overview of Maternal Morbidity During Hospitalization for Labor and Delivery in the United StatesObstetrics & Gynecology, 2009
- Soluble Endoglin and Other Circulating Antiangiogenic Factors in PreeclampsiaNew England Journal of Medicine, 2006
- Soluble endoglin contributes to the pathogenesis of preeclampsiaNature Medicine, 2006
- Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia developAmerican Journal of Obstetrics and Gynecology, 2004
- Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for PreeclampsiaThe Journal of Clinical Endocrinology & Metabolism, 2004
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJournal of Clinical Investigation, 2003
- Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?Human Reproduction, 2000